A Canadian cannabis company has debuted a new fast-acting product for the country’s medical cannabis market.
The new quick-dissolving strips, which use proprietary QuickStrip technology, come in tetrahydrocannabinol (THC) and cannabidiol (CBD) varieties.
According to Tilray, the strips have a thin edible film containing micronized cannabinoids that dissolve directly into the bloodstream.
Tilray says the strips offer patients fast-acting, convenient, precise doses for relief from a range of conditions.
Tilray CEO and Chairman Irwin Simon says the company’s medical brands, Aphria, Symbios, and Tilray, are relentlessly committed to patient wellness through a range of new innovative product offerings, GMP-certified cultivation, and the medical community’s earned trust.
“The launch of the Aphria-branded medical strips is a compelling proof point in this regard, and, given the growing expansion of medical cannabis across the globe, we believe we are exceptionally well-positioned in this high-growth, high-margin market moving forward.” says Simon. “We look forward to extending our leadership in medical cannabis and to delivering value for patients and shareholders alike.”
The strips are available throughout Canada and come in three cannabinoid ratios, THC 10, CBD 20:1, and a soon-to-be-released THC:CBD 10:10 formulation.
Each package of Aphria oral strips contains 30 individually wrapped, precisely-dosed strips.
Tilray Canada President Blair MacNeil says Aphria Medical’s goal is to be the trusted partner for patients by offering them high-quality, precise, and efficacious medical treatment.
“Delivering on this mission means meeting patients ‘where they are,’ including those who are unable or reluctant to swallow medication or do not prefer the taste of cannabis oil,” says MacNeil. “To address this need, Aprhia has pioneered a superior, non-combustible, discreet, and easy-to-use method of consumption that utilizes micronized cannabinoids for rapid absorption and relief from a range of conditions.”